Complete Genomics, a struggling DNA sequencing company in Silicon Valley, said on Monday that it had agreed to be acquired for USD 117.6 million by BGI-Shenzhen, a Chinese company that operates the world’s largest sequencing operation. The deal will need antitrust clearance, because of two key players in the DNA sequencing business in a highly capital intensive and research intensive industry, as well as clearance from a national security review by the Committee on Foreign Investment in the United States. It also requires approval from certain governmental authorities in China.
Featured News
FTC Targets Personalized Pricing as Algorithms Reshape Retail
Aug 19, 2026 by
CPI
UK Watchdog Opens Pricing Probes Into Trainline, Virgin Atlantic and RED Driving School
Aug 19, 2026 by
CPI
Google’s $12.2 Billion Marvell Deal Deepens Ties Across AI Supply Chain
Aug 19, 2026 by
CPI
Australian Competition Regulator Searches WiseTech in Antitrust Probe
Aug 19, 2026 by
CPI
Judge Approves Google’s $700 Million Play Store Settlement
Aug 19, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes